Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
- PMID: 26016841
- DOI: 10.1177/1753465815587820
Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
Abstract
The discovery of epidermal growth factor receptor activating mutations (EGFR Mut+) has determined a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. However, despite these impressive results, most patients with NSCLC EGFR Mut+ develop acquired resistance to TKIs. This review will discuss both the mechanisms of resistance to TKIs and the therapeutic strategies to overcome resistance, including emerging data on third-generation TKIs.
Keywords: AZD9291; CO-1686; HM61713; T790M mutation; epidermal growth factor receptor activating mutations; non-small cell lung cancer; tyrosine kinase inhibitors.
© The Author(s), 2015.
Similar articles
-
Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?Drug Des Devel Ther. 2015 Oct 15;9:5641-53. doi: 10.2147/DDDT.S52787. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26508839 Free PMC article. Review.
-
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.Lung Cancer. 2016 Mar;93:59-68. doi: 10.1016/j.lungcan.2016.01.003. Epub 2016 Jan 8. Lung Cancer. 2016. PMID: 26898616 Review.
-
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.Curr Opin Oncol. 2015 Mar;27(2):94-101. doi: 10.1097/CCO.0000000000000164. Curr Opin Oncol. 2015. PMID: 25611025 Review.
-
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613. J Cancer Res Ther. 2016. PMID: 28230005 Review.
-
Emerging treatment for advanced lung cancer with EGFR mutation.Expert Opin Emerg Drugs. 2015;20(4):597-612. doi: 10.1517/14728214.2015.1058778. Epub 2015 Jul 8. Expert Opin Emerg Drugs. 2015. PMID: 26153235 Review.
Cited by
-
Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors.Transl Lung Cancer Res. 2023 Jun 30;12(6):1197-1209. doi: 10.21037/tlcr-22-832. Epub 2023 Jun 12. Transl Lung Cancer Res. 2023. PMID: 37425421 Free PMC article.
-
EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.Oncotarget. 2017 Aug 9;8(43):75712-75726. doi: 10.18632/oncotarget.20095. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088904 Free PMC article. Review.
-
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.Onco Targets Ther. 2016 Sep 6;9:5461-73. doi: 10.2147/OTT.S94745. eCollection 2016. Onco Targets Ther. 2016. PMID: 27660463 Free PMC article. Review.
-
The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition.Pharmacol Res. 2022 Jan;175:105998. doi: 10.1016/j.phrs.2021.105998. Epub 2021 Nov 24. Pharmacol Res. 2022. PMID: 34826601 Free PMC article.
-
Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy.Asian J Pharm Sci. 2020 Jan;15(1):26-41. doi: 10.1016/j.ajps.2019.06.001. Epub 2019 Jul 5. Asian J Pharm Sci. 2020. PMID: 32175016 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
